Can you take HRT with dense breasts? Usually, yes: dense breast tissue by itself is not a standard reason to rule out hormone therapy. But density raises your starting breast cancer risk and can hide cancer on a mammogram, and estrogen-plus-progestogen HRT can make breasts denser, so the HRT type and your screening plan matter most.
One thing comes first. If your mammogram calls for diagnostic pictures or a biopsy, or you've noticed a new breast change, follow up on that before an HRT decision. A BI-RADS 3 result is different: it calls for planned short-interval imaging and a conversation with your prescriber, not an automatic HRT ban. If your report was otherwise normal, density is part of the HRT conversation, not a stand-alone "no."
Find your situation:
| If this is you… | What it usually means | Best next step |
|---|---|---|
| Your report says dense (C) or extremely dense (D), and the finding was negative or benign (BI-RADS 1 or 2) | HRT is usually still on the table. The type of HRT matters. | Read the type table below and bring your report to the consult |
| You're already on combined HRT and the latest report says dense | Common. Combined HRT can raise density. | Don't stop on your own. Ask about your screening plan and your regimen. |
| Your main problem is vaginal dryness, pain with sex or repeat UTIs | Low-dose vaginal estrogen is a different, low-absorption treatment | Ask about local treatment first |
| You'd rather not take hormones | Non-hormonal prescriptions exist for hot flashes | See the options section |
| Extremely dense plus a BRCA gene change, strong family history, past atypical biopsy or chest radiation | Your risk may call for a different screening plan | Get a personal risk assessment first |
| BI-RADS 3 — probably benign, with a short-interval follow-up recommended | Low likelihood of cancer, but the imaging plan matters | Keep that follow-up and discuss the report with your HRT prescriber before choosing a provider |
| BI-RADS 0, 4, 5 or 6, a new lump, or a personal history of breast cancer | An unfinished or serious breast finding needs a separate care plan | Complete diagnostic care or see your breast/oncology team first |
Not sure which numbers your report shows? Read the two answers on your mammogram report. It takes two minutes and changes your next step.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
What we actually verified · Last verified October 2026 We checked source text and published study reports or abstracts on October 26, 2026: the National Cancer Institute's dense-breasts page (updated October 19, 2026); the American Cancer Society's mammogram-report guide (revised July 23, 2026); the published records of the Women's Health Initiative density studies, the PEPI trial, and studies by Kerlikowske (2010), Byrne (2017), Buist (2009) and Grady (2007); the American College of Radiology's density-specific 2024 update published in 2025; Pfizer's Duavee prescribing highlights; Gala Health's hormone-health page and two Gala HRT landing pages; and The HRT Index's Find My HRT Path tool. We confirmed: combined estrogen-plus-progestogen therapy raised mammographic density in randomized trials; estrogen alone raised it less; the A/D risk estimates in our comparison match the published Kerlikowske study abstract and were converted from percentages to counts; Gala lists estradiol pills and patches, progesterone, vaginal estradiol and non-hormonal options, and one of its HRT pages advertises $69 a month. We did not: sign up with any provider, pay, talk to a clinician, or calculate anyone's personal risk. This is a documentation review. We could not confirm: The Menopause Society's exact current wording on breast density; whether Gala asks for mammogram results; which exact products or non-hormonal drugs it currently dispenses; whether the $69 headline covers multiple prescriptions; its exact billing cycle, HRT-specific refund terms or its amount due today. Some links on this page are affiliate links. We may earn a commission if you start care through them. That never changes our safety guidance. How we make money.
Can you take HRT with dense breasts? The honest answer
Most women with dense breasts can still consider HRT. Density is common, and it isn't on the standard lists of reasons not to use hormones. The tradeoff is real, though: combined estrogen-plus-progestogen therapy can make breasts denser and is associated with higher breast-cancer risk in some studies, while greater density can make mammograms harder to read.
So the honest answer has three parts.
First, density alone isn't a "no." A contraindication is a firm medical reason not to use a treatment, like a past breast cancer, a blood clot or unexplained bleeding. Breast density isn't one of those. It's a risk factor: something that raises the odds, like family history or age. You can read the full list in our guide to HRT contraindications.
Second, density changes the stakes. If your breasts are dense, you start with a higher baseline risk than a woman with fatty breasts. In one large observational study we break down below, combined-HRT users with extremely dense breasts had higher estimated risk than users with fatty breasts. That doesn't close the door. It means the type of HRT, the dose, how long you use it and how you're screened all matter more for you.
Third, experts genuinely disagree on how cautious to be. Breast researchers and menopause clinicians may give different weight to this tradeoff. The evidence shows that density and some types of HRT affect risk, but it cannot decide for you how that risk weighs against symptoms that disrupt your life. Ask for a discussion of the actual risk and the treatment type, not a yes-or-no rule based on one word in your report.
Our editorial take: you deserve a real conversation, not a reflex. Dense breasts plus miserable hot flashes is a decision you can make with good information, the right HRT type and a screening plan you understand.
What if a clinician told you dense breasts mean no HRT?
Ask one question: "Is density the reason, or is it something else in my report or history?" Sometimes the real concern is a pending follow-up, a past atypical biopsy or a strong family history, and "dense breasts" was shorthand. If density truly is the only reason, it's fair to ask whether lower-density options (below) or a formal risk assessment would change the answer. If you still disagree, a second opinion from a menopause-trained clinician is reasonable. The Menopause Society explains how to find a clinician and identify certification in its practitioner guide.
How do you read a dense-breast mammogram report before choosing HRT?
Your mammogram report gives two separate answers. One is a density grade (A, B, C or D) that describes how your tissue looks. The other is an assessment number (BI-RADS 0 to 6) that says whether anything suspicious was found. Mixing them up is the most common reason women panic after a "dense" letter.
Grab your report or patient-portal result now. Look for two lines.
Answer 1: your breast density grade (A–D)
Radiologists use a system called BI-RADS (Breast Imaging Reporting and Data System) to grade density. Since September 10, 2024, mammography facilities covered by federal rules must tell you in writing whether your tissue is dense or not dense (FDA). Your letter will say something close to "Your breast tissue is dense," with a note that other tests may help some women (NCI).
| Density grade | What it means | Share of women (NCI) | Counted as "dense"? | Does it mean cancer? | What it changes for the HRT talk |
|---|---|---|---|---|---|
| A — almost entirely fatty | Mostly fat; easiest to read | About 10% | No | No | Density adds no special concern |
| B — scattered fibroglandular | Mostly fat with some dense areas | About 40% | No | No | Routine HRT risk discussion |
| C — heterogeneously dense | Many dense areas that may hide small masses | About 40% | Yes | No | Ask how density, your overall risk and the HRT type fit together |
| D — extremely dense | Almost all dense tissue; mammograms are least sensitive | About 10% | Yes | No | Ask whether your total risk calls for extra screening and which HRT types add least density |
Source: National Cancer Institute, Dense Breasts, updated October 19, 2026.
A few things worth knowing. You can't feel density; a radiologist assesses it on mammography. Density often runs in families, drops with age and having children, and is higher in women with a lower body weight and in women using menopausal hormone therapy (NCI). And it can shift from one mammogram to the next, partly because radiologists don't always grade the same images identically.
Answer 2: your BI-RADS assessment (0–6)
This number is about findings, not tissue type. It's what tells you whether anything needs follow-up.
| Assessment | What the radiologist is saying | Usual next step (ACS) | What it means for an HRT decision |
|---|---|---|---|
| 0 — incomplete | Needs more views, an ultrasound or comparison with old images | More imaging | Finish the workup first. "Dense" plus 0 is not a normal mammogram yet. |
| 1 — negative | Nothing new or abnormal | Routine screening | Reassuring. Density still belongs in the risk conversation. |
| 2 — benign | A finding that is not cancer | Routine screening | Same as 1 for planning purposes |
| 3 — probably benign | At most 2% likelihood of cancer, not a diagnosis | Repeat imaging, often in 6–12 months | Keep the imaging appointment and review it with your HRT prescriber; not an automatic ban |
| 4 — suspicious | Biopsy should be considered | Biopsy as recommended | Breast team first. Not an online HRT moment. |
| 5 — highly suggestive of cancer | Strong concern | Biopsy strongly recommended | Breast team first |
| 6 — known cancer | Cancer already confirmed by biopsy | Cancer care | Oncology team leads any menopause treatment decision |
Source: American Cancer Society, Understanding Your Mammogram Report, revised July 23, 2026. The last column is our plain-language guide, not medical clearance.
The mix-up to avoid: density D is not BI-RADS 4. "Density D, BI-RADS 1" means extremely dense tissue and nothing suspicious on that exam. "Density C, BI-RADS 0" means dense tissue and an unfinished exam that needs more pictures. Those are very different weeks.
A normal result is good news, but no mammogram can promise there's no cancer. That's especially true with dense tissue. And any new lump, bloody nipple discharge or skin change needs a clinician's look even if your last report was clean.
Five examples: same word "dense," different next steps
All examples are fictional. They show what information matters, not whether anyone will be prescribed anything.
| Example | What the report says | The question still open | Next useful step |
|---|---|---|---|
| Lena, 49, hot flashes wrecking her sleep; no family history | Density C, BI-RADS 1 | Does she have a uterus? Which HRT type fits? | Talk with a menopause clinician about HRT type and screening. Online care may fit. |
| Rosa, 52, mother diagnosed with breast cancer at 44 | Density D, BI-RADS 1 | Is her overall risk high enough to change screening or HRT choice? | Ask for a formal risk assessment before assuming routine online HRT |
| Dana, 48, got a callback letter | Density C, BI-RADS 0 | What do the extra pictures show? | Finish the diagnostic imaging first. Then share the result with any prescriber. |
| June, 55, only vaginal dryness and pain with sex | Density C, BI-RADS 2 | Does she need whole-body hormones at all? | Ask about low-dose vaginal treatment first |
| Ann, 60, recently diagnosed | Density D, BI-RADS 6 | What symptom care fits alongside cancer treatment? | Her breast/oncology team leads. Non-hormonal options are the usual starting conversation. |
If you're Lena, you're ready for the rest of this page. If you're Dana or Ann, the most caring thing we can say is: follow your breast-care plan first. This page will still be here.
Your situation changes the answer.
The right online menopause care isn't the same for every woman — it depends on your symptoms, what you've already tried, your age, your state and your health history. Some situations belong with an in-person clinician first. Use The HRT Index's Find My HRT Path tool to explore a featured care option for your situation — and to flag when online care isn't the right starting point — before your first consult.
It's free, takes about 60 seconds and doesn't ask for your email. It asks five questions: what's bothering you most, what you've tried, your age, your state and any health history a clinician should know about. It doesn't read mammograms or ask about breast density, so keep your report handy for the consult. If your assessment is 0, 4, 5 or 6 or you have a new breast symptom, contact your breast-care team first. With BI-RADS 3, keep the short-interval imaging plan and discuss it with your prescriber; the quiz cannot assess those findings.
What do dense breasts mean, and why do they matter for HRT?
Dense breasts have more gland and fiber tissue than fat. That matters for two separate reasons: dense tissue raises breast cancer risk on its own, and it can hide a cancer on a mammogram because both show up white. HRT can touch both problems, mostly through combined estrogen-plus-progestogen therapy.
Reason 1: density makes mammograms harder to read
On a mammogram, fat looks dark gray. Dense tissue looks white. So do many tumors and calcium spots. Finding a small cancer in a dense breast is a bit like spotting a snowball in a snowstorm. That's why mammography is less sensitive (more likely to miss a cancer) in dense breasts, and why women with dense breasts are called back for extra pictures more often (NCI).
Reason 2: density raises risk on its own
Women with dense breasts have a higher chance of developing breast cancer than women with fatty breasts. That's separate from the masking problem (NCI). Scientists are still working out exactly why.
The reassuring part
Dense breasts are normal and very common. Nearly half of women 40 and older who get mammograms are told they have them (NCI). And NCI reports that women with dense breasts who are diagnosed with breast cancer are no more likely to die from it than women with fatty breasts, after accounting for other health and tumor factors.
Density is one factor among many: age, family history, past biopsies, weight, alcohol, and how long you've used hormones. That's why a single word on a letter can't decide your HRT question.
Does HRT make your breasts denser?
Combined estrogen-plus-progestogen HRT reliably makes breasts look denser on mammograms, usually within the first year. Estrogen alone adds much less. One FDA-approved combination that uses bazedoxifene instead of a progestogen showed no density increase in a one-year trial, and low-dose vaginal estrogen has very little data.
Here's what the trials actually measured. "Points" means the change in the share of the breast that looks dense on the mammogram.
What each type of HRT did to breast density in studies
| HRT type | What happened to density | Study | What it means for you | Does Gala list it? |
|---|---|---|---|---|
| Estrogen (conjugated equine estrogens) + medroxyprogesterone acetate, an older synthetic progestin | Rose 6.0 points at 1 year vs a 0.9-point drop on placebo; still higher at 2 years | WHI randomized density substudy, 413 women (McTiernan, 2005) | The clearest, best-measured density rise | No |
| Estrogen + micronized progesterone (the body-identical form), taken 12 days a month | Density rose; the odds of a density increase were about 7 times higher than with estrogen alone | PEPI randomized trial (Greendale, 1999) | "Bioidentical" progesterone did not avoid the density rise in this trial | Yes (progesterone) |
| Estrogen alone (for women without a uterus) | Rose 1.6 points at 1 year vs a 1.0-point drop on placebo | WHI randomized substudy, 435 women (McTiernan, 2009) | A small rise; only an option if you've had a hysterectomy | Yes (estradiol pill or patch) |
| Very-low-dose estradiol patch (0.014 mg a day) | No increase over 2 years | Randomized trial, 276 women with mammograms (Grady, 2007) | Studied for bone protection; usually lower than a typical hot-flash dose | Not specified |
| Conjugated estrogens + bazedoxifene (brand Duavee) | No significant change vs placebo at 1 year; the estrogen + progestin comparison group did rise | SMART-5 density substudy, 940 women (SMART-5 primary trial) | An FDA-approved systemic option with one-year trial data showing no significant density increase; this is not proof of lower breast-cancer risk. For women with a uterus. | No |
| Low-dose vaginal estrogen | Very little data on density | DenseBreast-info review, 2024 | Not shown to raise breast cancer risk in women without breast cancer | Yes |
| Compounded "bioidentical" hormones | No reliable density data | — | No evidence they're gentler on breasts | Gala's pages conflict on compounding; ask |
Checked October 26, 2026. Trial numbers are group averages. Your own change could be bigger, smaller or none.
Three things this table tells you
1. Combined regimens raised density more than estrogen alone in these studies. Estrogen alone nudged density up a little in WHI. Adding a progestogen produced a larger rise in the combined regimens studied. That pattern also appeared in PEPI, including the micronized-progesterone group; it does not quantify every current dose or product.
2. "Bioidentical" doesn't mean breast-neutral. Many women hope micronized progesterone avoids the density problem. In PEPI, it didn't. It raised density about as much as the synthetic progestin regimens did. Micronized progesterone may have other advantages, and newer observational studies suggest it may carry less breast cancer risk than older synthetic progestins. But for density specifically, the trial evidence doesn't show a free pass.
3. A patch isn't proven to fix density. DenseBreast-info's review says combined HRT raised density whether it was taken as a pill or through the skin. A patch may offer a lower blood-clot risk than an oral estrogen regimen, but we found no strong trial evidence that switching to a patch prevents a density rise when systemic progestogen is also used. Be wary of anyone who promises that.
A clue worth mentioning: new breast soreness
In the WHI trial, women who developed new breast tenderness after starting combined HRT had much bigger density increases: 11.3 points at one year, compared with 3.9 points for women without new tenderness (WHI breast tenderness analysis). Soreness by itself is not a cancer diagnosis, and many women feel it early on. But if your breasts become newly sore on combined HRT, tell your prescriber. It's a useful clue for the conversation about your dose and your next mammogram.
How much does HRT add to breast cancer risk if your breasts are already dense?
In a large U.S. observational study, estimated five-year breast cancer risk changed very little across HRT groups with fatty breasts but was higher among HRT users with extremely dense breasts, especially those using estrogen plus progestin. For women aged 55 to 59 with extremely dense breasts, five-year risk was about 2.4% without HRT, 3.0% on estrogen alone and 4.2% on estrogen plus progestin.
Percentages are hard to feel. So we turned the study's published numbers into people.
Out of 1,000 women aged 55 to 59, how many were diagnosed with breast cancer within 5 years?
| Breast density | No HRT | Estrogen only | Estrogen + progestin |
|---|---|---|---|
| Almost entirely fatty (old BI-RADS 1, today's A) | About 8 | About 9 (reported together with combined) | About 9 |
| Extremely dense (old BI-RADS 4, today's D) | About 24 | About 30 | About 42 |
Source: Kerlikowske et al., Journal of Clinical Oncology, 2010. Observational risk-model estimates from 587,369 women and 1,349,027 screening mammograms in the Breast Cancer Surveillance Consortium. Published five-year modeled risks of 0.8%, 0.9%, 2.4%, 3.0% and 4.2% for ages 55–59 with assumed body mass index 25, multiplied by 10 to give "per 1,000." The 0.9% estimate covers both estrogen-only and combined users in the fatty-breast group. Heterogeneously dense (C) figures and formulation details are not presented in this short table. These are not randomized effects of starting a modern HRT regimen.
What those numbers mean in plain words
- With fatty breasts, the modeled estimates barely differed by HRT use: about 8 per 1,000 without HRT versus 9 per 1,000 among HRT users.
- With extremely dense breasts and no HRT, about 24 of 1,000 were diagnosed in five years. That's density's own effect.
- For estrogen-only users, the estimate was about 6 more per 1,000 than for nonusers in that dense group.
- For combined-HRT users, the estimate was about 18 more per 1,000 than for nonusers. That's a meaningful observed difference, not a prediction of what starting HRT would cause for one woman. It also means about 958 of every 1,000 women in that group were not diagnosed in those five years.
In the same study, hormone users with extremely dense breasts had about 1.7 times the odds of an advanced-stage cancer diagnosis compared with hormone users who had average breast density. That is an association between groups, not a finding that HRT itself caused the stage difference. That's a reason to take screening seriously. It isn't a reason to panic.
The authors' conclusion was measured: postmenopausal women with high density should know HRT adds risk, especially estrogen plus progestin.
Why the density change may matter too
A later analysis of the WHI trial looked at how much each woman's density rose in her first year of combined HRT (Byrne et al., JNCI, 2017). Each 1-point rise in density was linked to about a 3% higher breast cancer risk. Women in the top fifth, whose density jumped more than 19 points, had about 3.6 times the risk. When the researchers accounted for density change, the extra risk from combined HRT disappeared from their model.
In plain terms: in that study, the density rise appeared to carry combined HRT's extra breast cancer risk. The authors suggested doctors consider density changes after combined HRT begins. At your next mammogram on the screening schedule you and your clinician choose, ask that it be compared with your previous images; the study is not a reason to schedule an extra mammogram on your own.
The honest limits
- This is observational data, mostly from older HRT products. It doesn't separate today's estradiol patches or micronized progesterone.
- The Byrne findings come from one older pill combination (conjugated estrogens plus medroxyprogesterone acetate).
- These are group averages, not your personal risk. Your age, weight, family history and past biopsies all move your number.
- For HRT and breast cancer numbers across all women, not just dense breasts, see our guide to HRT breast cancer risk by type.
Which HRT options may fit when you have dense breasts?
The right option depends on your symptoms, whether you have a uterus and your overall breast risk. With dense breasts, it often helps to ask whether local vaginal treatment would address local symptoms, whether estrogen alone is an option if you have had a hysterectomy, and what combined therapy means for density when you still have a uterus. This is a list of options to discuss with a clinician, not a prescription.
First, two terms. Systemic therapy travels through your whole body; pills, patches, gels and sprays treat hot flashes and night sweats. Local therapy works mostly where you put it; low-dose vaginal estrogen treats dryness, pain with sex and some urinary symptoms.
HRT routes compared for women with dense breasts
| Option | Treats | What the density and breast evidence shows | Uterus? | Listed by Gala? | Who might ask about it |
|---|---|---|---|---|---|
| Low-dose vaginal estradiol | Vaginal dryness, painful sex, help preventing repeat UTIs | Minimal absorption; very little density data; not shown to raise breast cancer risk in women without breast cancer | No progestogen usually needed at low local doses | Yes (cream or tablets) | Women whose main problems are vaginal or urinary |
| Estrogen alone (pill or patch) | Hot flashes, night sweats, sleep | Small density rise in WHI; WHI estrogen-alone did not show increased breast cancer incidence in women who had a hysterectomy | For systemic estrogen used without a progestogen, generally only after hysterectomy | Yes (estradiol) | Women without a uterus |
| Estrogen + micronized progesterone | Hot flashes, night sweats; protects the uterine lining | Density rose in PEPI; expect a possible rise | Needed if you have a uterus and take systemic estrogen | Progesterone listed; confirm exact micronized product | Women with a uterus who want whole-body relief |
| Conjugated estrogens + bazedoxifene (Duavee) | Hot flashes; prevents bone loss | No significant density rise vs placebo in one year; cancer-risk effect is not established by that finding | For women with a uterus | No | Women with a uterus who want to limit density change |
| Non-hormonal prescription (e.g., fezolinetant) | Hot flashes and night sweats | No estrogen added; has its own risks and monitoring | Not applicable | Non-hormonal category listed; fezolinetant itself not confirmed | Women who can't or would rather not use hormones |
| No new medicine | — | Doesn't change your density or screening needs | — | — | Women with mild symptoms |
Evidence checked October 26, 2026. Gala column reflects Gala's own HRT pages, read the same day.
If your main problem is vaginal dryness or pain with sex
Low-dose vaginal estrogen is often the gentlest place to start. Very little of it reaches your bloodstream. DenseBreast-info's 2024 evidence review found it hasn't been shown to raise breast cancer risk in women who haven't had breast cancer, though there's very little data on density specifically. It won't fix hot flashes. If you've had breast cancer, this is a conversation for your oncology team; see vaginal estrogen after breast cancer. More on how it works: our vaginal estrogen guide.
If you've had a hysterectomy
Estrogen alone is usually the whole-body option. It raised density only a little in WHI, and in that trial estrogen alone didn't raise breast cancer risk. Some observational studies disagree, so "reassuring" is the honest word, not "risk-free."
If you still have a uterus
Systemic estrogen by itself can thicken the uterine lining and raise the risk of endometrial (uterine lining) cancer. That's why women with a uterus take a progestogen — progesterone or a similar hormone — alongside it. The tradeoff with dense breasts is that estrogen-plus-progestogen regimens in older trials increased density more than estrogen alone. Questions worth asking:
- What's the lowest dose that controls my symptoms?
- Should my next mammogram be compared closely with my last one?
- Is a hormonal IUD already protecting my lining? (That's a clinical decision, not something to assume.)
- Would Duavee be a reasonable alternative for me?
About Duavee (conjugated estrogens + bazedoxifene)
Duavee pairs estrogen with bazedoxifene, a drug that acts against estrogen in some tissues, instead of a progestogen. It's FDA-approved for hot flashes and preventing bone loss in women with a uterus (Pfizer prescribing highlights, revised March 2024). In its one-year density substudy, it did not raise density significantly more than placebo. That does not prove it lowers breast-cancer risk, and it is not an extra estrogen or progestogen to stack with another regimen. Its currently displayed prescribing highlights (revised March 2024) warn about uterine cancer, cardiovascular events and probable dementia, and list a current or past breast-cancer diagnosis among contraindications. Its patient leaflet still advises a yearly breast exam and mammogram unless your provider says otherwise. No U.S. generic was listed in January 2026 (Drugs.com); current pharmacy stock and coverage still need checking. Gala does not list Duavee, so you would need a prescriber who can confirm whether it is available for you. The FDA approved some other HRT labeling revisions in February 2026, but those changes do not establish a new Duavee label or remove the need to review its product-specific warnings (FDA).
If you'd rather avoid hormones
Non-hormonal prescriptions can ease hot flashes. Fezolinetant (Veozah) is FDA-approved for this. Its label carries a boxed warning about rare but serious liver injury and requires liver tests before starting, monthly for the first three months, then at months six and nine. Those tests and their costs need a separate plan, especially with cash-pay online care. Low-dose paroxetine is another FDA-approved option. Each has its own side effects. See non-hormonal options and fezolinetant for hot flashes.
What about compounded "bioidentical" hormones?
Compounded hormones are mixed by a pharmacy and aren't FDA-approved finished drugs. There's no reliable evidence they're easier on breast tissue. FDA-approved estradiol and micronized progesterone are already "bioidentical." Ask for the exact product name. More in compounded vs FDA-approved HRT.
If your symptoms are mild
Treatment is optional. Nobody has to start HRT just because menopause is happening. Keep up your screening either way.
Ready to talk through options? If your mammogram was negative or benign, nothing needing diagnostic workup is pending, and you don't have the red flags above, Gala advertises clinician-reviewed vaginal estradiol, estradiol with progesterone and non-hormonal care, with a $69/month headline on one HRT page. Confirm the exact medications, any extra costs and your first charge before paying. Have your density grade and last mammogram date ready, and ask how the clinician will factor them in.
Affiliate link. We may earn a commission if you choose Gala. A clinician decides whether any treatment is right for you; a prescription isn't guaranteed.
Will HRT make your mammograms harder to read?
It can. Combined HRT raised the chance of an abnormal mammogram that needed more tests in the WHI trial, and density makes small cancers harder to spot. But pausing HRT for one or two months before a mammogram didn't reduce callbacks in a randomized trial, so keep screening and tell the technologist you're on HRT.
More callbacks on combined HRT
In the WHI density study, women on combined HRT were about 3.9 times as likely as women on placebo to have an abnormal mammogram after one year (McTiernan, 2005). Interestingly, the density rise didn't fully explain that. An abnormal result usually means more pictures, not cancer. But callbacks are stressful and sometimes lead to biopsies.
Should you stop HRT before your mammogram?
A randomized trial tested this directly. Researchers asked 1,704 women already using HRT to keep going, pause for one month, or pause for two months before their screening mammogram (Buist et al., Annals of Internal Medicine, 2009).
| Group | Women | Called back for more imaging |
|---|---|---|
| Kept taking HRT | 542 | 11.3% (61 of 542) |
| Paused 1 month | 478 | 12.3% (59 of 478) |
| Paused 2 months | 451 | 9.8% (44 of 451) |
The differences weren't statistically meaningful. Density dropped only slightly with a pause, and women who paused had more hot flashes, night sweats and sleep problems. The authors found no support for a short break. Notably, 61% of eligible women declined to join the study; reluctance to pause treatment was an important limitation.
One more detail from that trial. Among women who kept taking HRT, the trial reported callback rates of 14.5% for those on combined therapy and 9.3% for those on estrogen alone. The trial wasn't designed to compare types, so treat that as a clue, not proof. It fits the density pattern above.
Don't change your treatment because of this page. If your prescriber or imaging center gives you instructions, follow them. For more on timing and costs, see do you need a mammogram before HRT.
Four ways to make each mammogram more useful
- Go back to the same facility when you can, or bring your old images. Comparison helps radiologists spot real changes.
- Tell the technologist you take HRT and when you started.
- Ask whether your center offers 3D mammography (tomosynthesis), which takes images from several angles. It can help in dense tissue, but it isn't the same as MRI and can't guarantee nothing is missed.
- Save the density and BI-RADS lines from every report so you can see your own trend.
Do you need an MRI, ultrasound or 3D mammogram because your breasts are dense?
Maybe. Expert groups weigh the evidence differently. The U.S. Preventive Services Task Force said in 2024 that evidence was insufficient to recommend for or against supplemental MRI or ultrasound after a negative mammogram for dense breasts alone. The American College of Radiology's newer recommendations distinguish both density and risk: at average risk, supplemental MRI may be appropriate for density C and is usually appropriate for density D. That is not the same as requiring an MRI for everyone with dense breasts.
Who says what about extra screening
| Group | Routine mammogram advice | Extra screening for dense breasts | Source |
|---|---|---|---|
| U.S. Preventive Services Task Force (2024) | Every 2 years, ages 40 to 74 | Not enough evidence to recommend for or against extra ultrasound or MRI after a normal mammogram | USPSTF |
| American College of Radiology (2024 update, published 2025) | Digital breast tomosynthesis improves sensitivity | At average risk, C density: MRI, abbreviated MRI or ultrasound may be appropriate; D density: MRI or abbreviated MRI is usually appropriate. At intermediate risk with C/D density, MRI or abbreviated MRI is usually appropriate; at high risk, MRI is usually appropriate regardless of density. | ACR Appropriateness Criteria |
| National Comprehensive Cancer Network | — | Supports considering extra screening (as summarized by NCI) | NCI |
| National Cancer Institute (summary, Oct 2026) | — | Some women with dense breasts may benefit; talk with your clinician about your risk | NCI |
Why the disagreement? Extra tests find additional cancers in some women. They also find more things that turn out to be harmless, which means more callbacks, more biopsies, more cost and more worry. The groups weigh those tradeoffs differently, and they look at slightly different questions. No guideline makes a mammogram density letter itself a prescription or a requirement for a specific scan.
The three extra tests, in plain words
- Breast MRI uses a magnet and contrast dye. It finds the most extra cancers but also the most false alarms. It's expensive and not for everyone.
- Breast ultrasound uses sound waves. No radiation. More false alarms than mammography alone.
- Contrast-enhanced mammography adds a dye to a mammogram. Sometimes used when MRI isn't possible.
A risk estimate is the best first step
Your density matters most when it's combined with everything else. Ask your clinician whether a risk tool that includes density fits your situation, such as the Breast Cancer Surveillance Consortium calculators (the official site links the current versions) or the Tyrer-Cuzick (IBIS) model. Women whose lifetime risk is high, or who carry a BRCA change, often follow a different screening plan entirely; some calculators are not designed for people with known inherited risk or previous cancer. These tools estimate breast cancer risk. They don't decide whether you can take HRT.
Will insurance pay?
It depends on your plan and your state. Screening, diagnostic callbacks and supplemental imaging are often billed differently. Before you book, ask: "Is this ordered as screening or diagnostic? Do I need prior authorization? What will I owe?" DenseBreast-info keeps a state-by-state map of laws about supplemental imaging coverage. Online HRT services do not perform mammograms themselves. Ask whether your clinician can order or coordinate imaging, and confirm which facility and insurer will bill you; Gala has not published a breast-imaging inclusion or coordination policy.
Already on HRT and your report says dense — what now?
Don't stop on your own because of a letter. Density on HRT is common, and stopping suddenly can bring symptoms back without clearly improving your next mammogram. Bring the report to your prescriber and ask whether your regimen, dose and screening plan still fit.
Many women find out they have dense breasts only after starting HRT, now that every report states it. That doesn't mean HRT caused it. Half of women 40 and older have dense breasts with or without hormones. And a callback doesn't mean HRT has harmed you; it means more pictures are needed.
Questions to sort out with your prescriber
- Was I dense before HRT? Pull up older reports. Going from B to C after starting combined HRT is a different story from always being C.
- How big was the change? Byrne's WHI analysis suggests a large jump in the first year is worth discussing.
- Does my overall risk now call for a risk estimate or extra screening?
- Is my current dose the lowest that works?
- Would a different route make sense for me? Vaginal-only if hot flashes have settled, estrogen alone if you've had a hysterectomy, Duavee if you have a uterus, or non-hormonal care.
- Are my breasts newly sore? Mention it (see the WHI tenderness finding above).
Will my breasts become less dense if I stop?
Often, somewhat. Density tends to fall after hormone therapy stops. Short pauses produce only small changes; in the Buist trial, density dropped by about 1 to 1.5 points after one to two months. Stopping is a real decision with real tradeoffs, including the return of symptoms and loss of bone protection. Make it with your prescriber. If you and your clinician decide to stop, ask how to do it in a way that fits your symptoms.
When should a breast specialist or in-person clinician be part of the decision?
Get a personal risk assessment before HRT if dense breasts come with other big risk factors, like a BRCA gene change, a strong family history, a past high-risk biopsy result or chest radiation. An unresolved diagnostic mammogram finding, new breast change or personal history of breast cancer calls for in-person breast care or specialist coordination first. A BI-RADS 3 short-interval surveillance plan should not be silently skipped, but is not the same as a suspicious biopsy recommendation.
Start in person or with a specialist if you have:
- An unresolved diagnostic workup: BI-RADS 0, 4 or 5, a scheduled biopsy; with BI-RADS 3, keep the scheduled short-interval follow-up and coordinate with the prescriber rather than assuming a blanket ban
- A new breast change: a lump, bloody nipple discharge, skin dimpling, or new pain in one spot
- A personal history of breast cancer, or another hormone-sensitive cancer
- A high-risk biopsy result such as atypical hyperplasia or lobular carcinoma in situ (LCIS)
- A known BRCA or other inherited risk gene, or relatives diagnosed young
- Chest radiation before age 30
- Extremely dense breasts plus a high calculated risk
If breast cancer runs in your family
Family history is not the same as having had cancer yourself. Many women with family history use HRT after a careful review. But which relatives, how young they were and whether a gene change is involved all matter. Dense breasts add one more factor to that picture. Read HRT with a family history of breast cancer.
If you've had breast cancer
Whole-body HRT is generally avoided after breast cancer, and the decision belongs with your oncology team. Low-dose vaginal estrogen and non-hormonal options are separate conversations.
If your clinicians disagree
Ask each to name the exact finding or risk behind their advice, and ask whether they can talk to each other. A new online prescriber should never be a way around an unfinished breast workup.
If you're over 60 or more than 10 years past menopause
Age and time since menopause change the systemic HRT picture for heart and clot risks, not just breast risk. That's a careful, personal conversation; see can you start HRT after 60.
Can you get HRT online if you have dense breasts?
Often, yes, if your mammogram was negative or benign, diagnostic findings are resolved and you do not have the red flags above. A BI-RADS 3 surveillance finding calls for a documented follow-up plan and prescriber review, not necessarily an automatic refusal. A good online clinician should ask about your breast history and screening and explain how each HRT type affects density. Online services can't do your mammogram, so you'll still arrange imaging locally.
What a good online intake should ask
- Your last mammogram date, density grade and BI-RADS result
- Any callbacks, biopsies or follow-up plans
- Personal and family breast cancer history
- Whether you have a uterus
- Your main symptoms: whole-body or vaginal
- Past HRT side effects, including breast soreness
If an intake never asks about breast history, that's a reason for caution. A careful service will sometimes say no, or send you to in-person care. That's a feature, not a flaw.
Gala Health HRT: our featured cash-pay option
Last verified October 2026 · Documentation review of Gala's public pages; we did not sign up, pay or speak with a Gala clinician.
Why Gala may fit women with dense breasts whose screening is settled: Its HRT pages list a useful range to ask a clinician about: vaginal estradiol for local symptoms, estradiol (pill or patch) with progesterone when appropriate for whole-body symptoms, and a non-hormonal category. The current public pages do not name a specific non-hormonal product such as fezolinetant, or independently establish which finished estradiol/progesterone products are dispensed. A licensed clinician reviews your history before prescribing. Gala's FAQ says, "We don't prescribe when the risk doesn't make sense" (Gala hormone-health page). Messaging, symptom check-ins and dose changes are included for as long as you're treated, and prescriptions ship free. One Gala HRT page advertises a flat monthly price with no membership fee, but checkout terms control the actual charge.
What Gala's pages say, and what's still open
| What you'd want to know | What Gala's pages say (read Oct 26, 2026) | Still to confirm before you pay |
|---|---|---|
| Medicines | Estradiol pill or patch; progesterone; vaginal estradiol cream or tablets; a non-hormonal category | Exact product names, manufacturers and whether fezolinetant is currently an available HRT option |
| FDA-approved or compounded | One HRT page says FDA-approved bioidentical forms; another page's footer says compounded drugs are not FDA-approved | Which you'd receive |
| Breast density or mammograms | Nothing published | Whether intake asks for your report and how it's used |
| Who reviews you | Gala says a U.S.-licensed provider typically reviews within 24 hours; a short video visit in some states | Individual clinician license, relevant medical assessment, service in your state and age group |
| Price | $69/month, "flat," on one HRT page (/lp/hrt1); no price shown on another HRT page (/lp/hrt) or the main hormone page | Amount due at checkout, exact charge date, billing interval and whether more than one prescribed product is included; minimum commitment not shown in the HRT offer |
| Insurance | Doesn't bill insurance; FSA and HSA accepted | — |
| Breast imaging | Gala does not publish a mammogram/MRI/ultrasound inclusion or coordination promise on these HRT pages | Ask who orders it, where it is billed and your insurance/out-of-pocket cost |
| Labs | Gala says routine hormone-level tests are usually not needed | Drug-specific required monitoring may still apply; ask whether tests, including all Veozah liver tests if offered, are arranged and covered |
| Ongoing care | Messaging, check-ins and dose changes included | Response times |
| Cancelling and refunds | "Cancel anytime" on Gala's HRT pages; general written policy, checked Oct 26, says notice must be received at least 72 hours before renewal and usually no refund for ordinary cancellation; medical disqualification has refund language | Confirm this policy governs HRT, the cutoff/time zone, service after cancellation, any minimum term, the handling of medical disqualification and conflicting wording on refund amount |
Gala is likely a good fit if you:
- Have density C or D with a negative or benign mammogram (BI-RADS 1 or 2) and nothing pending
- Have no personal breast cancer history and no unresolved high-risk finding, inherited-risk concern or specialist referral
- Want to compare vaginal, whole-body and non-hormonal options with one clinician
- Are comfortable with the HRT checkout price, an FSA/HSA card if eligible, message-based care and your state/age availability
Start somewhere else if you:
- Need insurance to pay for visits, or want your provider to order and coordinate breast imaging
- Specifically want Duavee (Gala doesn't list it)
- Have an unresolved BI-RADS 0, 4 or 5 finding, BI-RADS 6, a new breast change or personal breast-cancer history; for BI-RADS 3, confirm the imaging-surveillance plan with your prescriber first
One candid limitation: Gala publishes no dense-breast or mammogram-specific intake policy on the HRT pages checked. Bring your report and keep track of the imaging plan with your breast-care team; do not assume Gala will review the images or arrange the tests. Give the clinician your density grade, BI-RADS result and last mammogram date, and ask how they'll factor in density when choosing between vaginal, combined and non-hormonal options. If insurance billing or coordinated local imaging is your priority, ask an in-network clinician or Midi (below) how they would handle the breast report and referrals before deciding.
On Gala's own HRT page, a patient listed as Donna, 55, says: "My provider kept tuning my dose until it felt exactly right for me." Gala chose and published that comment. We can't verify it, and it isn't evidence of how treatment will go for you.
What Gala could cost: worked math
Gala's HRT page advertised $69 a month on October 26, 2026. Another Gala HRT page showed no price that day, so confirm the amount on your checkout screen. Here's the math if each charge is $69. These are billing illustrations, not a quote for your HRT medications. Gala's general refund policy says billing begins on completing intake, while another HRT page says you are charged if approved; the actual first-charge timing and HRT-specific terms remain to be confirmed.
| Period | If billed every calendar month | If billed every 28 days from day 1 | What could add to it |
|---|---|---|---|
| Due today | Not verified; $69 only if one advertised cycle is charged now | Not verified; $69 only if one advertised cycle is charged now | Possible extras and the policy for a declined prescription: confirm before checkout |
| First 90 days | 3 × $69 = $207 | 4 × $69 = $276 | Labs if ordered (unknown); any medication not covered (unknown) |
| First 365 days | 12 × $69 = $828 | 14 × $69 = $966 (30-day billing would be 13 × $69 = $897) | Same unknowns |
| Breast imaging | Gala does not publish an included imaging benefit | Ask where separate imaging or referral fees would be billed | Amount unknown until facility/insurer quote |
These examples assume charges on day 1 and renewals strictly every calendar month, 28 days, or 30 days. Actual charges depend on Gala's billing terms, start date and cancellation. Unknown required costs are not zero; any such total is incomplete.
Six questions to ask Gala before you pay
- "What exact estradiol, progesterone or non-hormonal product would I receive, and is it FDA-approved or compounded?"
- "What's charged today, is that before or after medical review, and when is my next charge?"
- "Does the monthly price cover both estradiol and progesterone if I need both?"
- "Will the clinician ask for my mammogram report, and how will my breast density affect what you recommend?"
- "If I'm prescribed fezolinetant, how are the required liver tests arranged and paid for?"
- "Which written HRT cancel/refund rules apply, what is the 72-hour cutoff, and what is refunded if the clinician declines to prescribe?"
If those answers work for you and your breast follow-up is settled, Gala is one way to request a licensed clinician's review. Share your density and full report yourself; Gala has not published a dense-breast review policy.
Affiliate link. We may earn a commission. A clinician decides whether treatment is appropriate.
For Gala's full complaints, billing details and cancellation rules, read our Gala Health HRT review.
Other routes worth knowing
| Route | What it publishes about mammograms | Insurance | Options relevant to dense breasts | Published price | Checked |
|---|---|---|---|---|---|
| Gala Health (affiliate) | No density-specific imaging policy published | Cash pay; FSA/HSA advertised | Vaginal estradiol, estradiol + progesterone, non-hormonal category (named drugs to confirm) | $69/month on one HRT page | Oct 26, 2026 |
| Midi Health (not an affiliate) | Ask whether its clinician can order and coordinate local breast imaging in your state | In-network with most PPO plans; no Medicaid/Medi-Cal; Medicare out of network, self-pay possible | Medication prescribing and outside-pharmacy route to confirm by treatment | Self-pay $250 first visit, $150 follow-ups | Oct 26, 2026 |
| Alloy (not an affiliate) | Updated mammogram required for recurring HRT prescriptions; a one-time fill may be considered at clinician discretion | Doesn't bill insurance | Published product menu | See Alloy cost | Oct 26, 2026 |
| Your OB-GYN or a menopause specialist | Orders and reviews your imaging | Usually | Full range, including Duavee | Depends on your plan | — |
If insurance or help coordinating imaging matters most, check Midi's pricing and insurance page for your state and plan. For the wider field, see our comparison of online HRT providers.
What should you bring and ask before starting or continuing HRT?
Bring your latest mammogram report, your family history and a clear list of the symptoms that bother you most. The most useful questions pin down whether the concern is density, an unfinished finding, inherited risk or a specific HRT type, and what screening fits you.
Printable companion to Can You Take HRT With Dense Breasts?. Keep this private and share it only with your care team. It does not interpret imaging, calculate risk, or decide what treatment you can take.
Build a private Dense-Breast HRT Appointment CardOptional · stays on this device
Everything you enter stays in this page while it is open. Nothing is saved, sent to The HRT Index, added to analytics, placed in a URL or shared with a provider. Closing or leaving the page clears the card.
This is an appointment-preparation aid, not a risk calculator, diagnosis, eligibility check or treatment plan. It cannot clear HRT or interpret an imaging result.
You can leave every field blank. Nothing is submitted.
Your take-to-your-appointment card
Copy or print this. Fill it in by hand or on your own device. Nothing here is sent to us.
MY DENSE-BREAST HRT CARD (keep private)
Last mammogram date: ______________ Facility: ______________
Breast density: A B C D (Was it different last time? ______)
BI-RADS assessment: 0 1 2 3 4 5 6
Follow-up recommended and date: ______________________________
Past biopsies or "atypical" results: __________________________
Breast cancer in family (who, age at diagnosis): ______________
Uterus: yes / no / not sure
Symptoms I most want to treat: hot flashes night sweats sleep
vaginal dryness painful sex UTIs other: ____
HRT or other medicines I take now (and start dates): _________
New breast soreness since starting? yes / no
My main question:
"Do my mammogram findings and my overall risk change whether whole-body
or local HRT makes sense for me — and what screening should I keep up?"Eight questions for your clinician
- "What's my BI-RADS assessment, separate from my density grade?"
- "Is anything pending that we should finish before deciding on HRT?"
- "Given my density and family history, what's my estimated breast cancer risk, and which tool did you use?"
- "Do I need a progestogen? If so, how will we watch for a density change?"
- "Which option adds the least density for my symptoms: vaginal-only, estrogen-only, combined, Duavee or non-hormonal?"
- "Would low-dose vaginal treatment handle my symptoms without whole-body hormones?"
- "When should my next mammogram be, and is extra screening worth it for someone with my risk?"
- "Is the medicine you'd prescribe FDA-approved, and what's its exact name?"
Source for BI-RADS meaning: American Cancer Society mammogram reporting guide. If a report needs diagnostic imaging, biopsy, or you have a new breast change, contact your breast-care team rather than using this card as clearance.---
How we researched this guide
We checked primary study reports or their published abstracts, government pages and provider pages behind the key numbers on this page, and dated the checks. This is editorial research, not medical review, and it can't tell you your personal risk.
Medical and regulatory facts come from the National Cancer Institute, the American Cancer Society, FDA-approved labeling, randomized trials (the Women's Health Initiative, PEPI, the Buist trial, and the primary SMART-5 published findings), large observational studies (Kerlikowske, Byrne) and screening guidelines (USPSTF, ACR). Provider facts come only from each provider's own pages, and describe only that provider. We used reader forums only to understand the questions women ask, never as medical evidence.
How The HRT Index Verification Standard applies to this question
| Pillar | What we looked for on this topic |
|---|---|
| 1. Clinical legitimacy | Does a licensed clinician review breast history before prescribing, and decline or refer when needed? |
| 2. Care quality | Does follow-up cover side effects like breast soreness, and does the service help with screening? |
| 3. Medication fit | Which density-relevant options are offered: vaginal, estrogen-only, estrogen + progestogen, Duavee, non-hormonal? Are products FDA-approved or compounded? |
| 4. Price transparency | What's due today, what recurs, what's included, and are imaging and labs outside the price? |
| 5. Access | Can a missing or old mammogram block a prescription or refill? Is insurance accepted? |
We don't give providers scores on this page. We earn commissions from some providers, including Gala, and we list providers we earn nothing from. Spot an error? Tell us; we log fixes on our corrections page. Full approach: methodology.
Can you take HRT with dense breasts? Quick answers
Is HRT contraindicated if you have dense breasts? No, not by itself. Density isn't on the standard contraindication lists. It raises the importance of which HRT you choose and how you're screened.
Is density D the same as an abnormal mammogram? No. A–D describes tissue. The BI-RADS assessment (0–6) tells you whether anything suspicious was found. Density D with BI-RADS 1 is a negative exam.
Does HRT make breasts denser? Combined estrogen-plus-progestogen therapy does, in randomized trials. Estrogen alone raises density a little. Duavee showed no significant change at one year. Vaginal estrogen has very little data.
Is micronized progesterone better for dense breasts? Not for density, based on the PEPI trial, where it raised density like the synthetic progestin regimens. It may differ in other ways, so discuss the full picture with your clinician.
Does an estrogen patch avoid the density increase? We found no strong evidence that it does. Combined HRT raised density whether taken by pill or through the skin, according to a 2024 evidence review.
Can you use vaginal estrogen with dense breasts? Usually it's the lowest-exposure option for vaginal and urinary symptoms. It hasn't been shown to raise breast cancer risk in women without breast cancer. If you've had breast cancer, ask your oncology team.
Should you stop HRT before a mammogram? A randomized trial found that pausing for one or two months didn't reduce callbacks and brought symptoms back. Follow your own prescriber's instructions.
Do dense breasts mean you need an MRI? Not automatically. The USPSTF finds insufficient evidence for or against supplemental ultrasound or MRI solely for dense breasts after a normal mammogram. The ACR's 2024 update, published in 2025, says MRI may be appropriate for average-risk density C and is usually appropriate for average-risk density D; recommendations also change with overall risk. Ask your clinician about the risks and costs.
Will my breasts get less dense if I stop HRT? Often somewhat. Decide about stopping with your prescriber, since symptoms and bone protection are part of the tradeoff.
Are women with dense breasts more likely to die of breast cancer? According to NCI, no, after accounting for other health and tumor factors.
Can you get HRT online with dense breasts? Often, if your mammogram was negative or benign and nothing needing diagnostic workup is pending. With BI-RADS 3, coordinate the existing surveillance plan with your prescriber. Imaging still takes place locally.
Does Find My HRT Path ask about breast density? No. It asks about your symptoms, what you've tried, your age, your state and health history such as past breast cancer. Bring your mammogram report to your consult.
Your next step, based on what's still unanswered
You now know what your report says, how much each type of HRT changes density and risk, and what screening options exist. The next step depends on what's still open.
- Your report needs diagnostic imaging or biopsy, or you've noticed a breast change: follow your breast-care plan. See the ACS guide to your mammogram report and call the facility that did your exam.
- High risk, gene change or past breast cancer: start with a specialist or your oncology team.
- Your report is settled and you want cash-pay online care: compare options with a Gala clinician, using the six questions above.
- You need insurance or imaging coordination: start with your own clinician or ask an in-network service like Midi what it can order or coordinate.
- You still aren't sure where to begin: that's exactly what our free tool is for.
The HRT Index's Find My HRT Path tool asks five quick questions about your symptoms, what you've tried, your age, your state and your health history. Then it shows a featured online option that fits your answers, or a clear flag when online care isn't the right starting point. It's free, takes about 60 seconds and doesn't ask for your email. It won't read your mammogram or decide whether HRT is right for you. A clinician does that.
And if you already have a clinician who knows your history, bringing them your card is a great next step too.
Sources
Breast density and mammogram reports
- National Cancer Institute. Dense Breasts: Answers to Commonly Asked Questions. Updated October 19, 2026; read October 26, 2026.
- American Cancer Society. Understanding Your Mammogram Report. Revised July 23, 2026; read October 26, 2026.
- U.S. Food and Drug Administration. Final Rule to Amend the Mammography Quality Standards Act. Effective September 10, 2024.
HRT and breast density
- McTiernan A, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005.
- McTiernan A, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the WHI randomized trial. J Clin Oncol. 2009.
- Crandall CJ, et al. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. WHI analysis.
- Greendale GA, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density (PEPI). Ann Intern Med. 1999.
- Grady D, et al. Effect of ultra-low-dose transdermal estradiol on breast density in postmenopausal women. Menopause. 2007.
- Harvey JA, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. SMART-5 primary density substudy, 2013; original 940-woman randomized substudy.
- DenseBreast-info. Does taking HRT or estrogen therapy alone affect breast density or breast cancer risk? Updated March 2024.
Breast cancer risk with density and HRT
- Kerlikowske K, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010.
- Byrne C, et al. Mammographic density change with estrogen and progestin therapy and breast cancer risk. J Natl Cancer Inst. 2017.
Mammograms on HRT and extra screening
- Buist DSM, et al. Short-term hormone therapy suspension and mammography recall: a randomized trial. Ann Intern Med. 2009 (Table 2).
- U.S. Preventive Services Task Force. Breast Cancer: Screening. 2024.
- ACR Expert Panel on Breast Imaging (Paulis LV et al.). ACR Appropriateness Criteria: Supplemental Breast Cancer Screening Based on Breast Density, 2024 Update. Published May 2025. Official ACR appropriateness ratings for average-risk extremely dense breasts distinguish MRI as usually appropriate.
- Breast Cancer Surveillance Consortium. Risk calculator tools. Read October 26, 2026.
- DenseBreast-info. State law insurance map.
Medicines
- Pfizer. Duavee prescribing highlights. Revised March 2024; read October 26, 2026.
- Drugs.com. Generic Duavee availability. Updated January 8, 2026; current stock or insurance coverage not established.
- DailyMed. Veozah (fezolinetant) prescribing label. Directly checked October 26, 2026; liver tests at baseline, monthly for three months, month six and month nine.
- FDA. February 12, 2026 menopausal hormone-therapy labeling revisions. First six products; not a general claim that all labels changed.
Providers (describe only that provider's own offer)
- Gala Health. Hormone health; HRT page with $69/month offer; HRT page with compounded-medication notice and Donna testimonial; general refund policy; terms. All read October 26, 2026; do not assume GLP-1 terms are HRT-specific without seeing the checkout agreement.
- Midi Health. Pricing & insurance. Checked October 26, 2026.
- Alloy. Do I need a mammogram? Checked October 26, 2026.
The HRT Index is an independent editorial publication. We are not a healthcare provider, pharmacy or telehealth service. Nothing here is medical advice, a diagnosis or a treatment plan. For decisions about starting, stopping or changing hormone therapy, talk with a licensed clinician who knows your history. In an emergency, call 911.
Keep reading: